Alzheimer’s Risk: New Protein Detected in Blood Raises Concerns
- A study published in January 2024 in eBioMedicine by researchers at Stony Brook University has revealed a significantly elevated level of tau protein in the blood of individuals...
- pTau-181 is a recognized biomarker associated with neurodegenerative diseases, including Alzheimer's disease.
- The findings suggest a potential link between COVID-19 infection and long-term neurological consequences.
Long COVID and Elevated Tau Protein Levels
A study published in January 2024 in eBioMedicine by researchers at Stony Brook University has revealed a significantly elevated level of tau protein in the blood of individuals experiencing neurocognitive issues following a COVID-19 infection. The research indicates an average increase of 59% in the pTau-181 protein level in 227 participants with long COVID, compared to their pre-infection baseline levels.
Understanding pTau-181
pTau-181 is a recognized biomarker associated with neurodegenerative diseases, including Alzheimer’s disease. Elevated levels of tau protein in the bloodstream are indicative of lasting brain damage. According to Dr. Sean Clouston, the study’s lead author and an epidemiologist at Stony Brook, “The presence of tau at higher levels in the blood is a known biomarker of lasting brain injury.”
Study Details and Implications
The findings suggest a potential link between COVID-19 infection and long-term neurological consequences. Further research is needed to fully understand the implications of these elevated tau levels and their potential impact on cognitive function and the development of neurodegenerative conditions. The study highlights the importance of continued monitoring and investigation into the long-term health effects of COVID-19.